Cite
MLA Citation
Gerd R Burmester et al.. “A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.” Annals of the rheumatic diseases, vol. 76, no. 6, 2017, pp. 1020–1030. http://access.bl.uk/ark:/81055/vdc_100137792097.0x000057